An official website of the United States government
Home
This disease is obsolete.
This neoplasm is not reportable EXCEPT for Brain and CNS Sites between 2021-2024.
Name
ICD-O-3 Morphology
9971/1: Polymorphic Post Transplant Lymphoproliferative Disorder (PTLD)
Effective
2021 - 2024
Reportability
This neoplasm is not reportable EXCEPT for Brain and CNS Sites between 2021-2024
Primary Site(s)
See Abstractor Notes
This hematopoietic disease is not reportable for the U.S. except for primary sites C700-C729, C751-C753.
Canada, refer to your specific province for reportability requirements.
See 9971/3 (for all primary sites) for years 2010-2021, 2025+
Canada, refer to your specific province for reportability requirements.
See 9971/3 (for all primary sites) for years 2010-2021, 2025+
Abstractor Notes
(This code is effective for cases diagnosed 2021-2024)
For 2021-2024, Polymorphic PTLD (PTLD by itself, no accompanying lymphoma, plasmacytoma, multiple myeloma) is coded as 9971/1 and is only reportable for CNS sites (C700-C729, C751-C753)
Post-transplant lymphoproliferative disorder, NOS is part of the Mature B-cell neoplasms lineage table in the WHO 5th edition of Hematolymphoid Tumors. (See Appendix B in the Hematopoietic Manual, Table B15)
For cases diagnosed 2010-2021 or 2025+, see 9971/3.
This code is not reportable prior to 2010.
Per the IARC/WHO Committee for ICD-O and included in the WHO Tumors of Hematopoietic and Lymphoid Tissues, Revised 4th Ed, Volume 2, PTLD by itself is a /1 starting in ICD-O-3.2. For the US and Canada, 9971/1 will be reportable for years 2021-2024 for CNS sites only.
Starting 1/1/25, PTLD (by itself [polymorphic]), will be reportable for any site and is to be coded as 9971/3.
Note that ICD-O-3.2 has this as 9971/1; however, the US will be collecting this as 9971/3 starting 1/1/25.
For 2021-2024, Polymorphic PTLD (PTLD by itself, no accompanying lymphoma, plasmacytoma, multiple myeloma) is coded as 9971/1 and is only reportable for CNS sites (C700-C729, C751-C753)
Post-transplant lymphoproliferative disorder, NOS is part of the Mature B-cell neoplasms lineage table in the WHO 5th edition of Hematolymphoid Tumors. (See Appendix B in the Hematopoietic Manual, Table B15)
For cases diagnosed 2010-2021 or 2025+, see 9971/3.
This code is not reportable prior to 2010.
Per the IARC/WHO Committee for ICD-O and included in the WHO Tumors of Hematopoietic and Lymphoid Tissues, Revised 4th Ed, Volume 2, PTLD by itself is a /1 starting in ICD-O-3.2. For the US and Canada, 9971/1 will be reportable for years 2021-2024 for CNS sites only.
Starting 1/1/25, PTLD (by itself [polymorphic]), will be reportable for any site and is to be coded as 9971/3.
Note that ICD-O-3.2 has this as 9971/1; however, the US will be collecting this as 9971/3 starting 1/1/25.
Alternate Names
Polymorphic lymphoproliferative disorders arising in immune deficiency/dysregulation (see 9971/3 for 2025+)
Definition
Post-transplant lymphoproliferative disorders (PTLD) are lymphoid or plasmacytic proliferations that develop as a consequence of immunosuppression in a recipient of a solid organ, bone marrow, or stem cell allograft. The early lesions are defined as lymphoid proliferations in an allograft recipient, characterized by architectual preservation of the involved tissue, with preservation of the nodular sinuses or tonsillar crypts, and residual or sometimes floridly reactive follicles in some cases.
Corresponding ICD-10 Codes (Cause of Death codes only)
D47.7 Other specified neoplasms of uncertain or unknown behavior of lymphoid, hematopoietic, and related tissue
Corresponding ICD-10-CM Codes (U.S. only)
D47.Z1 Post-transplant lymphoproliferative disorder (PTLD) (effective October 01, 2015)
Sources
International Classification of Diseases for Oncology, Third Edition, Second Revision. Geneva: World Health Organization, 2020.
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
